MCL1 and leukemia: As shown in this study, dinaciclib has direct anti-leukemia cytotoxicity but effects are of short duration, suggesting that it needs to be combined with chemotherapy or other novel agents whose activity may be enhanced by dinaciclib-induced down-regulation of Mcl-1 in acute leukemias.